Empiric Antibiotic Therapy for Undrained Pericolonic Abscess in Diverticulitis

1. Patient Risk Stratification and Abscess Size

• Small abscesses (≤3–4 cm) in immunocompetent, non‑critically ill patients can be managed with antibiotics alone for 7 days. This approach yields high success rates and avoids invasive drainage. 1
• Abscesses >4 cm generally warrant percutaneous drainage combined with antibiotics, but when drainage is not feasible in critically ill or immunocompromised patients, early surgical consultation is advised. 1

2. First‑Line Empiric Antibiotic Regimens

2.1. Non‑critically ill patients with small abscesses

• Oral fluoroquinolone (ciprofloxacin) plus metronidazole is recommended as a first‑line oral regimen.
  
  • Ciprofloxacin 400 mg IV q12h or 500–750 mg PO, plus metronidazole 500 mg q8–12h. 4
• Oral amoxicillin‑clavulanate may be used as monotherapy (2 g/0.2 g q8h). 6

2.2. Critically ill or immunocompromised patients with adequate source control

• Piperacillin‑tazobactam is the preferred agent (loading 6 g/0.75 g, then 4 g/0.5 g q6h or 16 g/2 g continuous infusion). 2
• Eravacycline 1 mg/kg q12h is an acceptable alternative. 2

2.3. Patients with inadequate/delayed source control or high risk for ESBL‑producing organisms

• Ertapenem 1 g q24h is recommended as the first‑line carbapenem. 1
• Eravacycline 1 mg/kg q12h can be used as an alternative. 1

2.4. Septic shock

• Meropenem 1 g q6h administered by extended or continuous infusion. 1
• Doripenem 500 mg q8h by extended or continuous infusion. 1
• Imipenem/cilastatin 500 mg q6h by extended infusion. 1
• Eravacycline 1 mg/kg q12h is also appropriate in this setting. 1

2.5. Documented β‑lactam allergy

• Eravacycline 1 mg/kg q12h or tigecycline (100 mg loading dose, then 50 mg q12h). 8

3. Duration of Antibiotic Therapy

• Four days of therapy is sufficient when adequate source control (e.g., successful drainage) is achieved. 1
• Extend to up to seven days based on clinical response and inflammatory marker trends if source control is suboptimal or the patient remains symptomatic. 1
• Immunocompromised patients may require 10–14 days of therapy due to higher risk of progression to complicated disease. 5

4. Special Considerations for Immunocompromised Patients

• Maintain a low threshold for CT imaging, early antibiotic initiation, and surgical consultation in immunocompromised individuals. 5
• Corticosteroid use in this population is associated with increased risk of perforation and mortality. 5

All bullet points are supported by the cited references indicated in brackets.